Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Herzog

Gynecologic Oncology Cincinnati, OH Medical Doctor

NPI 1619909850 CMS profile 163892

2139 Auburn Ave, Cincinnati, OH 45219

Open in the dashboard

General payments

$584,886

538 records reported · program years 2019–2025

Research payments

$2,750

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,079,486 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Thomas Herzog of Cincinnati, OH is reported in the CMS Open Payments database as having received $584,886 across 538 general payments and $2,750 in research payments paid to them. Separately, studies naming them as principal investigator received $1,079,486 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $79,503 67
2024 General $69,955 76
2023 General $72,693 74
2022 General $103,034 98
2021 General $88,648 54
2020 General $80,135 39
2020 Research $2,750 1
2019 General $90,919 130

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Herzog
  • Gynecologic Oncology median
  • Middle half of Gynecologic Oncology
  • National median

In program year 2025, general payments to Thomas Herzog were reported at $79,503. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.

Show as a table
Year Thomas Herzog Gynecologic Oncology median Middle half National median
2019 $90,919 $287 $113–$1,548 $163
2020 $80,135 $223 $59–$2,164 $114
2021 $88,648 $193 $68–$1,139 $132
2022 $103,034 $252 $90–$1,151 $149
2023 $72,693 $281 $102–$1,419 $160
2024 $69,955 $308 $108–$1,502 $164
2025 $79,503 $305 $111–$1,499 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $186,695 185 payments
  2. GlaxoSmithKline, LLC. $87,942 47 payments
  3. Merck Sharp & Dohme Corporation $45,021 39 payments
  4. Eisai Inc. $35,663 18 payments
  5. Aadi Bioscience, Inc. $32,490 19 payments
  6. AstraZeneca UK Limited $28,245 9 payments
  7. Clovis Oncology, Inc. $26,665 36 payments
  8. TESARO, Inc. $17,867 31 payments
  9. Alkermes, Inc. $13,590 12 payments
  10. Daiichi Sankyo Inc. $12,355 17 payments
  11. Other $98,352 125 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $459,531 167 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $52,020 15 payments
  3. Travel and Lodging $29,929 70 payments
  4. Honoraria $27,361 8 payments
  5. Food and Beverage $15,970 277 payments
  6. Education $76 1 payment
Products named General payments · program years 2019–2025
  1. LYNPARZA $168,620 147 payments
  2. Lenvima $29,965 12 payments
  3. Rubraca $26,101 31 payments
  4. JEMPERLI $24,760 11 payments
  5. Fyarro Cancer $23,691 11 payments
  6. KEYTRUDA $12,145 16 payments
  7. ENHERTU $10,134 12 payments
  8. ZEJULA $8,134 21 payments
  9. FYARRO Immunosuppressant $6,462 5 payments
  10. Hemoblast $6,329 10 payments
  11. Other $76,643 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $2,750 1 payment

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$43,680

Medicare's payments for the services billed

Medicare patients

112

Average age 70

Services billed

427

112 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 48%
Cancer 46%
Depression 29%
Diabetes 27%
Ischemic heart disease 27%
Chronic kidney disease 19%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $4,797
  • AstraZeneca UK Limited $2,055
$6,852 — —
JEMPERLI
  • GlaxoSmithKline, LLC. $6,467
$6,467 — —
EPKINLY
  • Genmab U.S., Inc. $6,026
$6,026 — —
TUKYSA
  • PFIZER INC. $4,050
$4,050 — —
ENHERTU
  • Daiichi Sankyo Inc. $3,768
$3,768 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

539 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecologic Oncology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record